CN105792833B - 用于通过增加hdl胆固醇水平治疗和/或预防疾病的基于甲基环糊精的组合物 - Google Patents

用于通过增加hdl胆固醇水平治疗和/或预防疾病的基于甲基环糊精的组合物 Download PDF

Info

Publication number
CN105792833B
CN105792833B CN201480065300.6A CN201480065300A CN105792833B CN 105792833 B CN105792833 B CN 105792833B CN 201480065300 A CN201480065300 A CN 201480065300A CN 105792833 B CN105792833 B CN 105792833B
Authority
CN
China
Prior art keywords
cyclodextrin
use according
methyl
methylcyclodextrin
cholesterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480065300.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN105792833A (zh
Inventor
马尔茨·萨洛米
丹尼尔·威尔斯
沙维尔·帕瑞斯邵克斯
弗朗索瓦·马奇
法布里齐奥·蒙泰库科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rogate Brothers
Original Assignee
Rogate Brothers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rogate Brothers filed Critical Rogate Brothers
Priority to CN201910316561.5A priority Critical patent/CN110123831A/zh
Publication of CN105792833A publication Critical patent/CN105792833A/zh
Application granted granted Critical
Publication of CN105792833B publication Critical patent/CN105792833B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201480065300.6A 2013-12-13 2014-12-12 用于通过增加hdl胆固醇水平治疗和/或预防疾病的基于甲基环糊精的组合物 Active CN105792833B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910316561.5A CN110123831A (zh) 2013-12-13 2014-12-12 用于通过增加hdl胆固醇水平治疗和/或预防疾病的基于甲基环糊精的组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1362633 2013-12-13
FR1362633A FR3014694B1 (fr) 2013-12-13 2013-12-13 Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl
PCT/FR2014/053309 WO2015087016A1 (fr) 2013-12-13 2014-12-12 Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910316561.5A Division CN110123831A (zh) 2013-12-13 2014-12-12 用于通过增加hdl胆固醇水平治疗和/或预防疾病的基于甲基环糊精的组合物

Publications (2)

Publication Number Publication Date
CN105792833A CN105792833A (zh) 2016-07-20
CN105792833B true CN105792833B (zh) 2021-06-25

Family

ID=50424476

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910316561.5A Pending CN110123831A (zh) 2013-12-13 2014-12-12 用于通过增加hdl胆固醇水平治疗和/或预防疾病的基于甲基环糊精的组合物
CN201480065300.6A Active CN105792833B (zh) 2013-12-13 2014-12-12 用于通过增加hdl胆固醇水平治疗和/或预防疾病的基于甲基环糊精的组合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201910316561.5A Pending CN110123831A (zh) 2013-12-13 2014-12-12 用于通过增加hdl胆固醇水平治疗和/或预防疾病的基于甲基环糊精的组合物

Country Status (15)

Country Link
US (2) US10022392B2 (fr)
EP (2) EP3082831B1 (fr)
JP (2) JP6322289B2 (fr)
KR (3) KR102453643B1 (fr)
CN (2) CN110123831A (fr)
AU (2) AU2014363270B2 (fr)
BR (1) BR112016013481A2 (fr)
CA (2) CA3180528A1 (fr)
DK (1) DK3082831T3 (fr)
ES (1) ES2859609T3 (fr)
FR (1) FR3014694B1 (fr)
MX (1) MX2016007658A (fr)
PL (1) PL3082831T3 (fr)
RU (1) RU2677889C1 (fr)
WO (2) WO2015087017A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150216895A1 (en) 2012-08-03 2015-08-06 The United States of America, as represented by the Secretary, Department of Health & Human Servic Cyclodextrin for the treatment of lysosomal storage diseases
JP2018517046A (ja) 2015-06-10 2018-06-28 ビテス， インコーポレイテッド ヒドロキシプロピル−ベータ−シクロデキストリン組成物および方法
FR3042501B1 (fr) * 2015-10-16 2017-11-03 Roquette Freres Nouvelles cyclodextrines methylees et leurs procedes de preparation
EP3432880A4 (fr) * 2016-03-20 2019-12-11 Asdera LLC Utilisation des cyclodextrines pour réduire l'endocytose dans les troubles malins et neurodégénératifs
WO2018009531A1 (fr) * 2016-07-08 2018-01-11 Ranedis Pharmaceuticals, Llc Compositions et méthodes de traitement et/ou de prévention de maladies de stockage lysosomal et d'autres maladies métaboliques monogéniques
KR101906578B1 (ko) * 2017-07-28 2018-10-10 경북대학교 산학협력단 사이클로덱스트린 및 vegf 과발현 줄기세포를 유효성분으로 포함하는 퇴행성 신경질환의 예방 또는 치료용 약학적 조성물
KR20200107927A (ko) 2017-09-28 2020-09-16 아스데라 엘엘씨 인지질 조절장애를 수반하는 질환 및 장애에서의 시클로덱스트린의 용도
CN107982546A (zh) * 2017-12-05 2018-05-04 中国药科大学 基于主客体相互作用的酸敏感超分子纳米粒及其应用
CN108342473A (zh) * 2018-04-13 2018-07-31 东华大学 一种用于检测血脂代谢相关基因abcg1甲基化的试剂盒
CA3104568A1 (fr) * 2018-06-29 2020-01-02 Roquette Freres Melange de molecules d'hydroxypropyl-.beta.-cyclodextrine et son procede de preparation
FR3083234B1 (fr) * 2018-06-29 2020-11-27 Roquette Freres Nouvelles hydroxypropyl-beta-cyclodextrines et leurs procedes de preparation
US11925659B2 (en) 2018-10-29 2024-03-12 Cyclo Therapeutics, Inc. Methods for treating Alzheimer's disease
CN113490691A (zh) * 2019-01-03 2021-10-08 劣势者药物有限公司 环糊精二聚体、其组合物及其用途
US11446325B2 (en) * 2020-09-30 2022-09-20 Cyclolab Cyclodextrin Research And Development Laboratory Ltd. Cyclodextrin derivatives in the treatment or prevention of lysosomal neurodegenerative diseases
FR3115682B1 (fr) * 2020-11-05 2023-02-24 Roquette Freres Compositions à base de méthyl-cyclodextrines pour le traitement et/ou la prévention de la stéatose hépatique
WO2023156966A1 (fr) 2022-02-18 2023-08-24 Beren Therapeutics P.B.C. Compositions d'hydroxypropyl-bêta-cyclodextrine et procédés de purification associés
WO2023156970A1 (fr) * 2022-02-18 2023-08-24 Beren Therapeutics P.B.C. Traitement de l'hypertriglycéridémie avec de la 2-hydroxypropyl-bêta-cyclodextrine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080032925A1 (en) * 2006-01-26 2008-02-07 University Of Medicine And Dentistry Of New Jersey Method for Modulating Inflammatory Responses by Altering Plasma Lipid Levels

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62265230A (ja) * 1986-05-12 1987-11-18 Kao Corp 高脂血症治療・予防剤
BE1006873A6 (nl) * 1993-03-26 1995-01-10 Merkus Franciscus W H M Toedieningsformulering voor nasale insuline toediening.
DE69833971T2 (de) * 1998-01-28 2006-11-02 Warner-Lambert Co. Llc Verfahren zur behandlung der alzheimerschen krankheit
MXPA02004743A (es) 1999-11-12 2003-10-14 Roquette Freres Mezclas cristalinas de eteres de metilo parciales de beta-ciclodextrina y compuestos relacionados.
AU2001253727A1 (en) * 2000-04-21 2001-11-07 The Trustees Of Columbia University In The City Of New York Methods for identifying compounds useful for preventing acute clinical vascular events in a subject
AUPR178300A0 (en) * 2000-11-29 2000-12-21 Heart Research Institute Ltd., The Cyclodextrins and reversal of atherosclerosis
TW200307011A (en) * 2002-04-18 2003-12-01 Chugai Pharmaceutical Co Ltd Hyaluronic acid modifier
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
BRPI0515191A (pt) * 2004-08-13 2008-07-08 Angiotech Internac Ag composição farmacêutica, método para aumentar osso ou substituir perda óssea, método para reduzir a dor associada com cicatriz pós-cirúrgica, método para prevenir aderência cirúrgicas, método para aumento ou reparo de pele ou tecido, método para manter volume em fluido ocular durante cirurgia ocular, método para reduzir a dor associada com osteoartrite, método para tratar doença de refluxo gastroesofágico, método para tratar ou prevenir incontinência urinária, método para tratar ou prevenir incontinência fecal, implante método e dispositivo médico
GB0421176D0 (en) * 2004-09-23 2004-10-27 Poston Robin Treatment of atherosclerosis
US9034846B2 (en) * 2004-10-10 2015-05-19 Universite De Liege Use of cyclodextrin for treatment and prevention of bronchial inflammatory diseases
EP1655034A1 (fr) 2004-10-10 2006-05-10 Université de Liège Utilisation d'un composé de cyclodextrine pour le traitement et la prévention des maladies inflammatoires bronchiques.
TW201006463A (en) * 2008-06-26 2010-02-16 Merz Pharma Gmbh & Co Kgaa Pharmaceutical compositions comprising aminocyclohexane derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080032925A1 (en) * 2006-01-26 2008-02-07 University Of Medicine And Dentistry Of New Jersey Method for Modulating Inflammatory Responses by Altering Plasma Lipid Levels

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A STUDY OF THE EFFECT OF METHYL-BETA-CYCLODEXTRIN ON CHOLESTEROL CONTENT AND VASCULAR RESPONSES OF THE PORCINE ISOLATED CORONARY ARTERY;D.M. BUSSEUIL等;《BRITISH JOURNAL OF PHARMACOLOGY》;20001231;第10页 *
Evaluation of Cholesterol Reduction Activity of Methyl-β- cyclodextrin Using Differentiated Human Neurons and Astrocytes;Manju Swaroop等;《Journal of Biomolecular Screening》;20120930;第1243-1251页 *

Also Published As

Publication number Publication date
KR102453643B1 (ko) 2022-10-12
CA2930489A1 (fr) 2015-06-18
FR3014694A1 (fr) 2015-06-19
BR112016013481A2 (pt) 2018-01-16
US11266680B2 (en) 2022-03-08
CA2930489C (fr) 2023-01-17
WO2015087016A1 (fr) 2015-06-18
EP3082831B1 (fr) 2021-01-06
AU2020200500B2 (en) 2021-08-12
AU2014363270A1 (en) 2016-05-19
US10022392B2 (en) 2018-07-17
JP2017500310A (ja) 2017-01-05
RU2677889C1 (ru) 2019-01-22
KR20210158867A (ko) 2021-12-31
ES2859609T3 (es) 2021-10-04
DK3082831T3 (da) 2021-04-12
FR3014694B1 (fr) 2016-11-11
EP3581188A1 (fr) 2019-12-18
MX2016007658A (es) 2016-09-26
KR102463677B1 (ko) 2022-11-07
JP2018123153A (ja) 2018-08-09
EP3082831A1 (fr) 2016-10-26
US20160361344A1 (en) 2016-12-15
WO2015087017A1 (fr) 2015-06-18
AU2020200500A1 (en) 2020-02-13
CN110123831A (zh) 2019-08-16
AU2014363270B2 (en) 2020-03-12
CN105792833A (zh) 2016-07-20
KR20210072129A (ko) 2021-06-16
US20180207198A1 (en) 2018-07-26
PL3082831T3 (pl) 2021-06-28
KR20160088874A (ko) 2016-07-26
CA3180528A1 (fr) 2015-06-18
JP6322289B2 (ja) 2018-05-09

Similar Documents

Publication Publication Date Title
CN105792833B (zh) 用于通过增加hdl胆固醇水平治疗和/或预防疾病的基于甲基环糊精的组合物
KR101753131B1 (ko) 클로피도그렐 및 설포알킬 에테르 사이클로덱스트린을 함유하는 제형 및 사용 방법
US4877778A (en) Method of enhancing lipophile transport using cyclodextrin derivatives
JP6625966B2 (ja) 希ガスが豊富な液体ならびにその調製及び使用の方法
WO2016158212A1 (fr) Composition alimentaire contenant du resvératrol et du nicotinamide mononucléotide
JPH02202817A (ja) ビス（３，５―ジー第三ブチル―４―ヒドロキシフェニルチオ）メタンの血液コレステロール低下及び抗アテローム性動脈硬化症剤としての用途
JP2003533478A (ja) （３ｒ，４ｒ）−δ８−テトラヒドロカンナビノール−１１−酸に基づく細胞増殖の低減方法
JP2009538895A (ja) トマト抽出物の治療的使用
US20110039796A1 (en) Natural Composition for Anti-Angiogenesis and Anti-Obesity
CN111542329A (zh) 包含石墨烯纳米结构的抗炎组合物
BR112020007629A2 (pt) composições de canabidiol e quitosana e métodos para utilizar as mesmas
WO2002047682A1 (fr) Composition ameliorant les lipides sanguins
KR20210137511A (ko) 비타민 k 투여에 의한 신속한 내피 기능 개선, 동맥 경직 감소 및 혈관 석회화 반전
US20230149412A1 (en) Compositions and Methods for Cellular Ageing, Stress Resilience, Autophagy, Inflammation and Longevity
KR20130113581A (ko) 헴프씨 추출물을 포함하는 동맥경화증 예방 및 치료용 조성물
AU2014200085B2 (en) Formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use
JPH08253415A (ja) 抗動脈硬化治療剤
Muir et al. The effects of lysophosphatidlycholine upon cholesterol metabolism in CaCo-2 cells
FR3034665A1 (fr) Composition comprenant de la vitamine k2, du zinc et de la vitamine d

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant